By Chris Wack
Elevai Labs and INmune Bio have recently entered into an exclusive licensing agreement for the worldwide manufacturing and processing technology of Good Manufacturing Practice (GMP) grade human umbilical cord-derived mesenchymal stromal cells (hucMSCs). This licensing agreement allows Elevai Labs to use INmune Bio’s proprietary EMx technology, reducing the cost of manufacturing hucMSCs compared to purchasing them outright.
Lower Costs and Enhanced Product Development
The utilization of EMx technology will enable Elevai Labs to incorporate manufactured hucMSCs into licensed topical cosmetic products, catering to the rapidly growing medical aesthetics skincare market. This licensing agreement exclusively grants Elevai Labs the license to employ EMx technology for the development and commercialization of licensed topical cosmetic applications.
Elevai Labs anticipates significant cost savings in its future topical cosmetic product development and manufacturing endeavors by utilizing EMx technology. Manufactured hucMSCs produced through this technology will adhere to cGMP standards, ensuring quality and efficacy comparable to market-purchased options.
Ethical Sourcing and Compliance
Under the agreement, Elevai Labs commits to manufacturing all licensed topical cosmetic products in compliance with cGMP regulations, as well as adhering to ethical sourcing and thorough screening of umbilical cords from healthy full-term newborns. This commitment reflects Elevai Labs’ dedication to responsible and sustainable practices.
Financial Considerations
In accordance with the agreement, Elevai Labs will pay an initial deposit for the license in two installments over a period of six months. A final technology transfer fee will be paid within two years of executing the agreement. Additionally, Elevai Labs will offer a nominal royalty on sales of licensed topical cosmetic products manufactured using the EMx technology as further consideration.
